		Monday, 12:05 - 1:30 PM Poster Viewing AL and ATTR amyloidosis
	Abstract Poster Nummer	Poster Title
Abstract I)	
117 123	P001 P002	Morbidity and mortality measured through "Days Alive and Out of Hospital" (DAOH) in patients with AL amyloidosis according to cardiac involvement and specific treatment. Selection of appropriate quality of life instrument to measure patient-reported outcomes in systemic light chain (AL) amyloidosis
124	P003 P004	Symptom burden and quality of life in AL amyloidosis patients among recently diagnosed and long-term survivors Performance of a survival staging system incorporating sST2 in patients with light chain amyloidosis
165	P005	Evaluation of the Patterns Leading to Diagnosis in Patients With Amyloid Light-Chain Amyloidosis Using the Komodo Database
	P006 P007	Healthcare resource utilization in patients with light chain amyloidosis in Europe Reduction of cardiac AL amyloid deposition after complete response visualized by PIB-PET imaging
	P008 P009	The impact of longitudinal strain (LS) response in patients with advanced cardiac AL amyloidosis CMR with 11 mapping in systemic light-chain (AL) amyloidosis: from cardiac amyloid regression to refining treatment response
231	P010 P011	Outcomes for patients with systemic light chain (AL) amyloidosis and Mayo stage 3B disease Finding a needle in a haystack: oligomer detection via urinary extracellular vesicles in AL light chain amyloidosis
265	P012	Longitudinal testing for measurable residual disease (MRD) using multiparametric flow cytometry in patients with systemic light chain amyloidosis
266 277	P013 P014	Racial differences in the cytogenetic underpinnings of light chain amyloidosis Evaluation of NT-proBNP as surrogate endpoint in AL amyloidosis: development of a platform for federated, multi-institution meta-analysis of randomized trials
	P015 P016	Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis Diagnostic Hospitalization and Associated Costs in Patients with Amyloid Light-Chain Amyloidosis
292	P017 P018	Atypical neurological presentation of immunoglobulin light-chain amyloidosis Characterization and outcome of patients with systemic AL amyloidosis requiring dialysis prior to initial therapy
325	P019	Beta-2-microglobulin and lactate dehydrogenase as prognostic parameters in light-chain amyloidosis
338	P020 P021	Diagnostic value of liver stiffness as marker of hepatic amyloid deposition in systemic AL amyloidosis The Pattern of Organ Responses Varies in Patients with Systemic Light-chain Amyloidosis (AL) and Heart or Kidney or Heart and Kidney Involvement Who Achieve Deep Hematologic Responses
	P022 P023	Outcomes of patients with AL amyloidosis and end-stage renal disease requiring dialysis Identifying symptoms of AL amyloidosis in electronic health records using natural language processing, ICD codes, and manually abstracted registry data
378	P024 P025	A revised real staging system for long-term renal survival in patients with AL amyloidosis with renal involvement Role of subcutaneous abdominal fat tissue aspiration in the diagnosis of systemic immunoglobulin light-chain amyloidosis
468	P026	Functional Status and Heart Failure Quality of Life Provide Incremental Prognostic Value in Light Chain Amyloidosis
	P027 P028	Heart and autologous stem cells transplantation in AL amyloidosis. Droidopa for Treatment of Refractiony Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series D
154	P029 P030	AL Amyloidosis – a reason to transplant MGUS phenotype? Daratumumab for the treatment of Relapsed/Refractory AL amyloidosis: Experience from the Amyloidosis Program of Calgary (APC)
176	P031	Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3b light chain amyloidosis: a phase 2 study by the European Myeloma Network
185	P032 P033	Role of Doxycycline in the treatment of patients with AL amyloidosis receiving Bortezomib-containing regimens in the frontline setting: Experience from the Amyloidosis Program of Calgary Effect of the presence of t(11;14) for patients with AL amyloidosis treated with Bortezomib-containing regimens: Experiences from the Amyloidosis Program of Calgary
	P034 P035	Cyclophosphamide, Bortezomib and Methylprednisolone for the treatment of AL amyloidosis: Updated report from the Amyloid Program of Calgary (APC) Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a phase II study
212	P036 P037	Treatment outcomes according to solvage chemotherapy modalities for relapsed/refactory AL anyloidosis Autologous stem cell transplantation in primary amyloidosis: a single centre experience
294	P038	Bortezomib-based induction therapy is associated with superior hematologic responses and survival after stem cell transplantation in patients with AL amyloidosis
	P039 P040	Venetoclax in Relapsed or Refractory AL Amyloidosis with t(11;14) and BCL2 overexpression. Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory AFFIRM-AL Phase 3 Study
339	P041 P042	Assessing clinical outcomes in patients with AL amyloidosis across different criteria for hematologic complete response: Results from ANDROMEDA Efficacy of bortezomib based regimens in elderly patients with newly diagnosed AL amyloidosis and heart failure.
408	P043 P044	Time to next treatment [TNT] is an independent program time the suggest of the information treatment of the suggest of the sug
418	P045	IsAMYP: a phase 2 single-stage study to evaluate the efficacy of isatuximab, pomalidomide and dexamethasone, in patients with AL amyloidosis not in VGPR or better after any previous therapy.
	P046 P047	Epidemiology of light-chain amyloidosis in Latin America: a retrospective analysis of 212 patients. Grupo Latinoamericano de Estudio del Mieloma Múltiple (GELAMM) Timeline change of AL amyloidosis treatment response and clinical outcomes, a single-centre experience from Turkey
	P048 P049	Autologous Stem Cell Transplantation in AL amyloidosis in two centers from Latin America Real-world data on safety and efficacy of upfront daratumumab-based therapy in patients with light chain (AL) amyloidosis and high plasma cell burden evaluated at 3 months
433	P050	Comparison of bortesomib-based induction regimens with other treatment modalities in patients with newly diagnosed systemic light chain amyloidosis.
442 471	P051 P052	Autologous stem cell transplantation (ASCT) remains effective therapy for systemic immunoglobulin light chain amyloidosis (AL): Experience from a single Australian Amyloidosis Service Daratumumab, pomalidomide and dexamethasone (DPd) in relapsed/refractory light chain amyloidosis previously exposed to daratumumab (NCT04270175): Interim results
	P053 P054	Functional Status and Heart Failure Quality of Life Improve Following Therapy in Light Chain Amyloid Cardiomyopathy Arial Fibrillianto Does Not Influence the Occurrence of Cerebrovascular Accidents Among Patients with Amyloidosis Arial Fibrillianto
116	P055 P056	Morbidity and mortality measured through "Days Alive and Out of Hospital" (DAOH) in patients with amyloidosis. Factors associated with morbidity and mortality, measured through "Days Alive and Out of Hospital" (DAOH) in patients with AL and ATTR amyloidosis.
119	P057	Significant tricuspid regurgitation is associated with adverse outcomes in patients with transthyretin amyloidosis.
	P058 P059	Prevalence of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy 1 Clinical findings and comorbidities in wtATTR patients with suspected amyloid neuropathy
	P060 P061	Identification of wild-type transthyretin cardiac amyloidosis in patients with recent CTS surgery Evolution of demographics of patients with transthyretin amyloid cardiomyopathy over time: implications for disease awareness strategies and future trial design
129	P062 P063	Descriptive analysis of women with transthyretin anyloid cardiomyopathy: examining the patient demographics of a growing patient population Assessment and Management of Older Patients with Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond
137	P064	Preservation of Left Ventricle Stroke Volume in Patients with ATTRwt Cardiac Amyloidosis Treated with Selective TTR Stabiliser Tafamidis
156	P065 P066	Implementation of a machine learning model to assess transthyretin amyloid cardiomyopathy risk in an external platform Clinical and Socioeconomic Differences Among Patients with Transthyretin Cardiac Amyloidosis Belonging to North and South of Chicago.
	P067 P068	Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients Diagnostic Path, Clinical Characteristics and Outcomes of Patients With ATTR Cardiomyopathy in Greece
206	P069 P070	Screening for transthyretin-related amyloidosis in patients with aortic stenosis undergoing aortic valve replacement Case series of the treatment journeys of patients who underwent heart transplantation for transthyretin (ATTR) cardiac amyloidosis, with subsequent confirmed orthopedic disease
275	P071	Factors Associated with Financial Toxicity in Patients with ATTR: Results From Amyloidosis Research Consortium's ATTR Treatment Affordability Patient and Caregiver Survey
	P072 P073	Characterisation of Austrian Transthyretin Amyloid Cardiomyopathy (ATTR-CM) patients enrolled in a Tafamidis (61mg) early access program Incidence and Risk Factors for Pacemaker Implantation in Light Chain and Transthyretin Cardiac Amyloidosis
	P074 P075	The relationship between NT-proBNP and perception of the severity of cardiac symptoms in TTR-CA: the moderating role of anxious and depressive symptoms Neurological symptoms of patients with transthyretin amyloidosis at first neurological presentation at the Amyloidosis Center of Lower Saxony
346	P076 P077	Incidence and factors associated with de novo atrial fibrillation in patients with wild-type transityretin cardiac amyloidosis Quality of Life in Patients with Transftyretin Amyloid Cardiomyopathy Treated with Intersen
355	P078	Prospective evaluation of an applied wt-ATTR-CM machine learning model to a United States (U.S.) health system electronic health record
381	P079 P080	Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Transthyretin Cardiac Amyloidosis. Tafamidis 61 mg for treatment of ATTR cardiomyopathy in daily clinical practice: an observational study
386	P081 P082	Transthyretin Cardiac Amyloidosis (ATTR-CA) and its rising awareness: Patient characteristics and survival in the Australian context Significant survival benefits with Diffunisal in patients with Transthyretin (TTR) Amyloidosis Cardiomyopathy (ATTR-CM); A retrospective analysis
398	P083 P084	Effect of Inotersen on global longitudinal strain in transthyretin cardiac amyloidosis Inotersen treatment in transthyretin amyloid cardiomyopathy results in early and sustained serum transthyretin knockdown
405	P085	Baseline ECG characteristics in ATTR-CM
105	P086 P087	REAL-WORLD EXPERIENCE WITH TAFAMIS AT CEPARM UNIVERSITY HOSPITAL. FEDERAL UNIVERSITY OF RIO DE JANEIRO. BRAZIL. REAL-WORLD EXPERIENCE WITH INOTERSEN AT CEPARM. UNIVERSITY HOSPITAL FEDERAL UNIVERSITY OF RIO DE JANEIRO. BRAZIL
	P088 P089	Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension Characteristics of patients with ATTR amyloidosis and the Ile107Val mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
141	P090 P091	Analysis of cardiac involvement in hereditary transthyretin amyloidosis after liver transplantation 4 Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with HATTR Amyloidosis with V122//T60A Variants: A Phase 4 Observational Study
152	P092	Transthyretin amyloid polyneuropathy in mainland China: a unicentric study
163	P093 P094	Phenotype and Clinical Outcomes of Hereditary Transthyretin Amyloidosis caused by p.Glu109Lys TTR Variant. A new endemic variant in Spain Comparison of disability: intradermal vasomotor nerves, intradermal sudomotor nerves, and intraepidermal sensory nerves in hereditary transthyretin amyloidosis
168	P095 P096	A descriptive analysis of patients with ATTR amyloidosis and a mixed phenotype from the Transthyretin Amyloidosis Outcomes Survey (THAOS) Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
199	P097 P098	Characterization of patients with hereditary Transthyretin Amyloidosis in a Register Study in Germany Hereditary Transthyretin Amyloidosis (ATTRv) in the Middle East: a short report of two confirmed cases
216	P099	How occupational needs can be obtained? A Semi-Structured Interview with Hereditary Transthyretin Amyloidosis patients.
	P100 P101	A rare case of late-onset hereditary ATTR Amyloidosis with cardiac and neurologic manifestation S Characteristics of patients with ATTR amyloidosis and the Ser77Tyr mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
	P102 P103	EFFECTIVENESS OF PATISIRAN FOLLOWING SWITCH FROM TAFAMIDIS FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED (hATTR) AMYLOIDOSIS WITH POLYNEUROPATHY Characteristics of patients with ATTR amyloidosis and the Ile68Leu mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
258	P104 P105	Characteristics of Patients With ATTR Amyloidosis and the Phe64Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS) Effect of tafamidis on disease progression in patients with non-Val30Met transthyretin amyloid polyneuropathy: a sub-study of the Transthyretin Amyloidosis Outcomes Survey (THAOS)
304	P106	Cardiological evolution of hereditary transthyretin amyloidosis (AhTTR) in patients with liver transplant
334	P107 P108	Hereditary Transthyretin Amyloidosis caused by p.Ser43Asn TTR Variant. Insights and possible founder effect in Ecuador. A-V block as presentation of cardiac amyloid caused by conduction tissue infiltration
	P109 P110	Comparing patient and clinician perspectives of ATTR amyloidosis: Insights from the development of the Transthyretin Amyloidosis Quality of Life (ATTR-QOL) Questionnaire Peritoneal dialysis is a valid treatment option in hereditary transthyretin amyloidosis
388	P111 P112	Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Electroneuromyographic findings in eighteen newly diagnosed patients
413	P113	Case series: p.Leu131Met transthyretin amyloidosis in a Danish family: Pure cardiac phenotype? 20 years of symptomatic and presymptomatic genetic testing for hereditary transthyretin amyloidosis (ATTR) in the Balearic Islands
421	P114 P115	Cardiac Screening of Amyloid TTR Pathogenic Variant Carriers: Complementary value of Echocardiographic Global Longitudinal Strain Imaging versus Bone scintigraphy Comparison of Amyloid Detection in the Skin and Tenosynovium of Transthyretin Amyloidosis Patients
	P116 P117	A rare TTR mutation determining severe cardiac and neurological amyloidosis Lung volume restriction and abnormal cardiopulmonary response to exercise: red warning lights in transthyretin cardiac amyloidosis
456	P118 P119	Evaluation and follow-up of the sudomotor function in a cohort of ATTRv patients from a non-endemic area The Relation between African American Race, Genotype, and Prognosis in Transthyretin Cardiac Amyloidosis
101		

466	P120	Pre-symptomatic genetic testing for hereditary transthyretin amyloidosis: a 20-year single-centre experience
480 298	P121 P208	Peripheral nerve and cardiac features in hATTR patients presenting with active disease V1221, LS8H and late-onset V30M in the US Prospective MALDI-TOF analysis of blood serum peptidome to predict the onset and progression of hereditary transthyretin amyloidosis.
250		
		Tuesday 12:05 - 1:15 PM Poster viewing
173	P122	Amyloid fibril formation is suppressed by UV irradiation
181 189	P123 P124	An additive destabilizing effect of two substitutions, T60I/V122I, in heterozygous compound TTRv amyloidosis Selective recognition of human small transthyretin aggregates by a novel monocional antibody
198	P125	Domain-domain interactions and dimerization of the human λ-III immunoglobulin light chain FOR005 investigated by NMR spectroscopy
239 293	P126 P127	ALBase: an updated platform to study immunoglobulin light chain sequences Structure-based peptides as novel therapeutic and detection tools in cardiac amyloidosis
318 368	P128 P129	Alternative pathogenic mechanisms and novel pharmacological approaches in gelsolin amyloidosis Coagulative and fibrinolytic blood proteases efficiently cleave human transthyretin (hTTR) oligomers in vitro to generate the amyloidogenic fragment hTTR(49-127)
370 371	P130 P131	Mechanism of Misfolding and Amyloid Aggregation of the λ6 Light Chains Filling the gap for transthyretin amyloidosis: biochemical and structural studies of in vitro and in vivo assembled amyloid fibrils
385	P132 P133	Modulation of transthyretin aggregation: role of preformed fibrils and heparin Circulating forms of plasma transthyretin in patients with wild-type transthyretin amyloidosis and effects of tafamidis
409	P134	Early Events of Immunoglobulin Light Chain Aggregation: Role of the C-terminus Disulfide Bond
434 437	P135 P136	Recommendations for Addressing the Translational Gap between Experimental and Clinical Research on Amyloid Diseases Proteolytic stability of amyloid isolated from human cataract eye lens
448 454	P137 P138	Clusterin in Alzheimer's disease: friend or foe? Study of berry distinct polymorphism in ATTR amyloidosis fibrils by cryo-EM
161 210	P139 P140	Cardiac proteotoxicity is resulting from a complex interplay of several molecular properties of anyloidogenic Light Chains Assessing immunoglobulin Light Chain Protein Stability and Stabilization by Pharmacological Chaperones Using Differential Scanning Fluorimetry
221	P141	Limited cardiomyocytes' growth response to stimulation with human plasma and phenylephrine predicts poor outcome in ATTR cardiomyopathy in an in-vitro model.
286 321	P142 P143	When Amyloid Occupies the Bone Marrow: Are the Responses of CD138-depleted Cells from Marrows with Interstitial Amyloid Archetypal? Exploring the in vitro effects of light chain-induced proteotoxicity on primary human cardiovascular system cells
396 455	P144 P145	Exploring Alzheimer's disease (AD) related human brain proteome with MALDI Imaging Mass Spectrometry in combination with shotgun proteomics Transthyretin (hTTR) Amyloid Fibrils Trigger Plasma Clotting by Activating the Intrinsic Pathway of Blood Coagulation: Implications in Cardiac Senile Systemic Amyloidosis
470	P146 P147	V30M TTR animal model displayed a downregulated expression of several chemokines in different immune cell populations
178 180	P148	In vitro treatment of light-chain amyloidosis plasma cells to characterize response to venetoclax
222 267	P149 P150	Frequent Occurrence of Fibrinogen Amyloidosis in Japanese Squirrels (Sciurus lis) Exercise suppresses mouse systemic AApoAll amyloidosis through enhancement of the p38 MAPK signaling pathway
270 285	P151 P152	Characterization of heterozygous ATTR Y114C amyloidosis-specific IPS cells BIP deletion leads to decreased cell viability and antibody production in multiple myeloma cell lines
315 326	P153 P154	Age-related amyloid deposition in C578L/6 mice: Pathological findings and characterization of the renal damage HEMOSTASIS DYSFUNCTION INDUCES SENILE APOA2 AMYLOIDOSIS IN A MOUSE MODEL
331	P155	Endocytic inhibitory drugs protect C. elegans from the toxicity of amyloidogenic light chains
337 345	P156 P157	Is C. elegans a good model of β2-microglobulin related amyloidosis? Expression hosts matter: Differences between immunoglobulin light chain (AL) full length proteins expressed in bacteria and human cells
361 395	P158 P159	Efficient transient expression of exogenous immunoglobulin light chain (AL) full length proteins from cultured human cells Strategies to induce amyloid light chain deposition in a transgenic mouse model
115 158	P160 P161	Prognostic Implication of Long/Itudinal Changes of Left Ventricular Global Strain after Chemotherapy in Cardiac Light Chain Amyloidosis Amyloid Valvular Heart Disease: A Look Beyond the Ventricular Walls
169	P162	Scintigraphy Scan with planar and SPECT imaging of the chest using Technetium 99m Pyrophosphate for the assessment of AL Amyloidosis: Comparison with an ATTR cohort of patients
196 197	P163 P164	A kit method for direct radiolabeling the amyloid reactive peptide p5+14 with technetium-99m (99mTC) for the detection of cardiac amyloidosis by SPECT/CT imaging Quantitative changes in organ-specific amyloid load in a patient with AL amyloidosis, measured by 124I-AT-01 PET/CT imaging, correlate with serum biomarkers
208 223	P165 P166	The role of speckle tracking echocardiography in the diagnostic assessment of cardiac amyloidosis and Fabry disease Assessment of Incidental Cardiac Uptake in Bone Stanlingraphy across Spain. ECCINGO Study
230 233	P167 P168	Valve disease in cardiac amyloidosis: an echocardiographic score Coronary flow reserve by PET 13N-Ammonia in patients with Hereditary Transthyretin Amyloidosis with and without cardiac involvement.
240 241	P169 P170	Differentiation of ATTR amyloidosis based on abdominothoracic organ-specific uptake of 124I-AT-01 (124I-p5+14) assessed by PET/CT imaging
242	P171	Detection of extracardiac amyloid in patients with ATTR amyloidosis by PET/CT imaging using the amyloidophilic radiotracer 124I-AT-01 (124I-p5+14) Myocardial stiffness evaluation using atrial kick in healthy controls and patients with cardiac amyloidosis: a pilot study
245 255	P172 P173	[99mTc]Tc-DPD Scintigraphy Associating Semi-Quantitative Methods for the Diagnosis of Cardiac Amyloidosis: Experience in an Endemic Area Myocardial Contraction Fraction (MCF): A Simple Measure of Myocardial Shortening That is Associated with Longitudinal and Circumferential Strain in Transthyretin Cardiac Amyloidosis.
290 291	P174 P175	90 Histological validation of cardiac 99mTc-DPD uptake in patients with cardiac transthyretin amyloidosis Is a change of the current echocardiographic red flag for left ventricular wall thickness useful in cardiac amyloidosis screening?
299 302	P176 P177	Proposis of light chain amyloidoss with biopsy-proven cardiac involvement Multi-inaging characterisation of cardiac phenotype in different types of amyloidosis
310	P178	Prognostic Implications of Clinical Phenotype and Severity of Cardiac Involvement in Patients Presenting with Immunoglobulin Light Chain Amyloidosis
344 377	P179 P180	Diagnostic performance characteristics of quantitative and semi-quantitative parameters of Tc99m pyrophosphate imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: The SCAN-MP Study DPD scintigraphy – a biomarker of microcalcifications rather than amyloid
383 390	P181 P182	Prognostic Role of Echocardiographic Right Ventricular Parameters in Patients with Wild-Type ATTR Cardiac Amyloidosis False positive bone-scintigraphy in elderly hypertrophic cardiomyopathy
399 412	P183 P184	Dual-echo turbo-spin-echo and 12-echo multi-spin-echo sequences are equivalent techniques for obtaining T2-Relaxometry data in hereditary transthyretin amyloidosis CARDIAC IMAGING FOR ASSESSING INVOLVEMENT IN ALAMYLOIDOSIS PATIENTS: EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
422	P185	Phenotyping of hypertrophic cardiomyopathies using echocardiography: amyloid, Anderson-Fabry and hypertensive heart disease
461 465	P186 P187	Multimodality cardiac imaging in differential diagnosis of infiltrative cardiomyopathy Quantification of left ventricular amyloid using 124+p5+14 (AT-01) and 18F-florbetapir positron emission tomography in AL and ATTR amyloidosis
467 469	P188 P189	Changes in Left Ventricular Myocardial Composition Following Targeted Plasma Cell Therapy in Light Chain Amyloidosis: A Cardiac Magnetic Resonance Study Evaluation of Echocardiographic Parameters for Prognostication in Patients with Systemic Light Chain Amyloidosis
473	P190	Central Nervous System damage in hereditary Transthyretin Amyloidosis: A multimodal MRI study
		Tuesday 7:00 - 7:30 PM; Poster Viewing
490	PLB001	Amyloid Multidisciplinary Hybrid Clinic: A novel model of care in the age of telehealth
489 484	PLB002	Burden of transthyretin a myloid cardiomyopathy in patients and caregivers: interim analysis of a large, ongoing, non-interventional study Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018
502	PLB003 PLB004	txazomib maintenance following initial therapy in patients with high-risk immunoglobulin light chain (AL) amyloidosis.
481 503	PLB005 PLB006	Macroglossia, a Sign of A.L. Amyloidosis in a Case of Recurrent Pleural Effusion Mid-term analysis of the Clinical Amyloidosis Registry in Germany
487 492	PLB007 PLB008	On bead de-glycosylation coupled with MALDI-TOF mass spectrometry provides a simple method for confirming light chain glycosylation and provides a sensitive method for residual disease detection Real World Patient, Advocate, and Caregiver Perspectives on Amyloidosis: Awareness, Knowledge Gaps, and Psychosocial Impact
485	PLB009	Real World Faulent, Advocate, and Caregiver Perspectives on Amyoloosis: Awareness, knowledge Gabs, and Psychosocial impact Renal histopathological scoring of amyloid deposits is crucial to assess disease progression in light-chain (AL) amyloidosis: a multicentre retrospective study
498 499	PLB010 PLB011	Retrospective Cohort Study of treatment with BCL-2 inhibitor Venetoclax in relapsed or refractory AL amyloidosis
494 500	PLB012 PLB013	Tafamidis medication adherence in patients with transthyretin cardiac amyloidosis (ATTR-CM) in a Japanese medical claims database The impact of renal histopathology on the renal outcome for newly diagnosed patients with AL amyloidosis
493	PLB014	The patient voice: development and results of a pilot patient experience data (PED) survey
497 496	PLB015 PLB016	The role of local complement expression in renal amyloidogenic light chain amyloidosis Transthyretin tetramer destabilization, marked by lower plasma transthyretin, is causally associated with increased risk of all-cause and cardiovascular mortality in the general population
495	PLB017	Two-year follow-up of the first case of systemic light chain amyloidosis treated with anti-B cell maturation antigen -CAR T cells
	1	Wednesday 12:05 - 1:20 PM; Poster Viewing
1		
109	P191 P192	Quantitative Sensory Testing: a good tool to differentiate between an asymptomatic carrier from an early symptomatic ATTRv amyloidosis patient? The Journey to Diaenosis of ATTR Amyloidosis: Burden of Early Disease
132 138	P192 P193	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data.
132 138 146 147	P192 P193 P194 P195	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Xumamoto University
132 138 146	P192 P193 P194 P195 P196 P197	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhance Electrocardigaria: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DECISION-MAKING IN CONFIRMED AND POTENTIAL CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential Sources of error in the identification and referral of amyloidosis to a tertiary center
132 138 146 147 150 153 166	P192 P193 P194 P195 P196 P197 P197 P198	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with A-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnosis: and therapeutic center for amyloidosis at Kumamoto University ExperienceS and DocCSION-MARKING IN CONFIRMED AND POTENTIAL CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to artirary center Higher Length of Stay and Readmission Burdein in Heart Failure Patients with Cardiac Amyloidosis Than Those without
132 138 146 147 150 153 166 207 228	P192 P193 P194 P195 P196 P197 P197 P198 P199 P200	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogaria: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DECISION-MAKING IN CONFIRMED AND POTENTIAL CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential Sources of error in the identification and referrai of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidosis Than Those without MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS' SURVEY Prevalence of pauci-symptomatic amyloid transthyretin cardiac amyloidosis in the general population
132 138 146 147 150 153 166 207 228 229 238	P192 P193 P194 P195 P196 P197 P197 P198 P199 P200 P201 P202	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DOCISION-MANKING IN CONFIRMED AND POTENTIAL CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidosis Than Those without MANAGEMENT AND PATIENT ETSIMATION OF AMYLINU LIGH ATTR/AILA (LARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidosis Than Those without MANAGEMENT AND PATIENT ETSIMATION OF AMYLINU LIGHT-ATTR/AILA (LARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Prevalence of pauci-symptomatic amyloid transthyretin cardiac amyloidosis in the general population Redefining the epidemiology of cardiac amyloidosis, a systematic review and meta-analysis of screening studies Finding a balance between specialist and local care: amyloidosis patient perspectives on a single-centre approach
132 138 146 147 150 153 166 207 228 229 238 243 250	P192 P193 P194 P195 P196 P197 P198 P199 P200 P200 P201 P202 P203 P204	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DOCISION-MANKING IN CONFIRMED AND POTENTILA CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidosis. Prove National Advectore Started Sta
132 138 146 147 150 153 166 207 228 229 238 243 250 251	P192 P193 P194 P195 P196 P197 P198 P199 P200 P201 P202 P203	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with A-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnosit: and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DECISION-MARKING INC ONFIRMED AND POTENTIAL CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidos. Prevalence of paul sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidos. Prevalence of paul-sources of error in the identification and referral of amyloidosis to a tertiary center MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS RFOM A PHYSICIANS' SURVEY Prevalence of paul-sources of error in the identification of anyloidosis in the general population Redefining the epidemiology of cardiac amyloidosis, A systematic review and meta-analysis of screening studies Finding a balance between specialist and local care: amyloidosis patient perspectives on a single-centre approach Multidisciphinary approach for the early detection of amyloid care failer experitives on a single-centre approach Artificial Intelligence-Enhanced Models To Predict Light Chain Amyloidosis from Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma Lumbar spinal stores
132 138 146 147 150 153 166 207 228 229 238 243 250	P192 P193 P194 P195 P196 P197 P198 P199 P200 P201 P202 P203 P204 P205 P206 P207 P208 P209 P200	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DOCISION-MANKING IN CONFIRMED AND POTENTILA CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidos. Prove Without MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIR (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS' SURVEY Prevalence of pauci-symptomatic amyloid transthyretin cardiac amyloidosis to a tertiary center approach Redefining the optical amyloidos, Systematic review and meta-analysis of screening studies Finding a balance between specialist and tocal care: amyloidosis the general population Multidisciplinary approach for the early detection of amyloidosis patient perspectives on a single-centre approach Multidisciplinary approach for the early detection of amyloidos is from Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma Lumbar spinal stensis syndrome as surrogate for transthyretin cardiac amyloidosis From Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma Lumbar spinal stensis syndrome as surrogate for transthyretin cardiac amyloidosis From Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma Lumbar spinal stensis syndrome as surrogate for transthyretin cardiac amyloidosis From Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma Lumbar spinal stensis syndrome as surrogate for transthyretin cardiac amyloidosis From Patients With Mon
132 138 146 147 150 153 166 207 228 229 238 243 250 251 254 295 322	P192 P193 P194 P195 P196 P197 P198 P199 P200 P202 P203 P204 P205 P206 P207 P208 P209	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with AL-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumanoto University EXPERIENCES AND DOCISION-MANKING IN CONFIRMED AND POTENTILA CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidos. Protoe without MANAGEMENT AND PATIENT ESTIMATION OF AMNCIDID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS' SURVEY Prevalence of pauci-symptomatic amyloid transthyretin cardiac amyloidosis to the general population Redefining the egideniology of cardiac amyloidosis patient perspectives on a single-centre approach Multidisciplinary approach for the early detection of amyloidosis from a tertiary tenter approach Multidisciplinary approach for the early detection of amyloidosis from Patients with Ardiegu cargual turnois surgery. Preliminary results of an ongoing study. Artificial Intelligence-Enhanced Models To Predic Light Chain Amyloidosis from Patients With Monoconal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma Lumbar spinal stenses syndrome as surgate for transthyretin cardiac amyloidosis from teaters with the advective and neta-anaryloidosis from a surgery approach for the early detection of amyloidosis from tatients with producing approach of a usporting the implementation of nuclear scintigraphy to support accurate diagnosis of cardiac amyloidosis in a non-specialist setting Amyloidosis and Its multfaces: A case report see Monday Real-life evaluation of an algorithm for the diagnosis of cardiac amyloidosis
132 138 146 147 150 153 166 207 228 229 238 243 250 251 254 295	P192 P193 P194 P195 P196 P197 P198 P199 P200 P201 P202 P203 P204 P205 P206 P207 P208	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease Manifestations of chronic heart failure in patients with A-amyloidosis and ATTR-amyloidosis. Prospective observation data. Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis? Diagnostic and therapeutic center for amyloidosis at Kumamoto University EXPERIENCES AND DECISION-MANKING IN CONFIRMED AND POTENTILL CARRIERS OF ATTR-RELATED GENETIC VARIANTS Potential sources of error in the identification and referral of amyloidosis to a tertiary center Higher Length of Stay and Readmission Burden In Haret Tailure Patients with Cardiac Amyloidos. Enclosed Amyloidos Stay and Readmission Burden In Haret Tailure Patients with Cardiac Amyloidos. How Patients With Cardiac Carmyloidos and Patients with Cardiac Carmyloidos. Patients with Cardiac Carmyloidos. Patients with Cardiac Carmyloidos. Patients with Cardiac Carmyloidos and Patients With Cardiac Cardiac Mayloidos. Patients with Cardiac Cardiacardia Cardiac Cardiac C

349 P212	Changes in the Journey to Diagnosis of Cardiac Amyloidosis in the Past 10 Years: Results from the Amyloidosis Research Consortium's 2017 Cardiac Survey and 2022 Amyloidosis Community Survey
365 P213	Prognostic Value of an Artificial Intelligence Enhanced ECG Model in Cardiac Amyloidosis
379 P214	Retrospective analysis of a patient cohort with suspicion of systemic amyloidosis, finally not confirmed
380 P215	Validation of Amylo-AFFECT, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
382 P216	The landscape of anyloidosis in Switzerland: Report of the Anyloidosis Registry
384 P217 403 P218	Low QRS voltages in cardiac amyloidosis: echocardiographic correlates and prognostic value
	Clinical impact of musculoskeltal pathology in patients with transthyretin-associated amyloidosis (ATTR): retrospective analysis of the case series from our center
406 P219 420 P220	EARLY DETECTION OF HEREDITARY AMVLOIDOSS ROLE OF COMBINING A-ECG TO CLINICAL IRSK SCORES FOR THE PREDICTION OF TRANSTHYRETIN AMVLOID CARDIOMYOPATHY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
420 P220 427 P221	
427 P221 432 P222	Prevalence and Implications of Classic ECG Findings in a Contemporary ATTR Cohort Prevalence of Daytime and Nightimic Central Appensin Patients with Cardia Campoidosis
436 P223 441 P224	The distribution of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry Amyloidosis diseases and shifting distribution of ATTR and AL From 2019 to 2012: a German single center experience.
441 P225	Aniyotoosis dagitoosis and simang dossidadon of Arita and Actification 2021; do German single Center expensive: Initial Experience of a Private Amyloidosis Center
458 P226	Immat Lapernice or a trivate anny modous center From symptoms and signs to diagnosis – Development of a simple screening tool for hereditary transthyretin amyloidosis (AmyloScan©)
463 P227	Determining anyloid subjects artorspective comparative study between a clinical, laboratory, imaging, and pathological model and mass spectrometry
464 P228	Determining annybiolosis in Latin America: Opportunities to increase disease awareness among finicians. Findings from the AMILO-LATM research group Cardiac amybiolosis in Latin America: Opportunities to increase disease awareness among finicians. Findings from the AMILO-LATM research group
477 P229	consist of mysels and consist opportant consist of the consist of
111 P230	Glomerula dubular real function in patients with Hereditary Transthyretin Amyloidosis (ATTR)
135 P231	Targeted sequencing of functionally selected genes in patients with wild-type transthyretin amyloidosis
215 P232	Detection of amyloidogenic FLC in serum as a non-invasive tool to facilitate the diagnosis of AL amyloidosis
226 P233	Immunoglobulin high-throughput sequencing in Monoclonal Gammopathy of Clinical Significance (MGCS): experience of the French Amyloidosis center
269 P234	Neurofilament light chain, an early biomarker for polyneuropathy in hereditary transthyretin-related (ATTRv) amyloidosis
283 P235	The Clusterin/von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL A-type Than from A-isotype Monoclonal Gammopathy Patients
308 P236	A spectrum of clinical phenotypes associated with p.(Arg54Giy) TTR variant.
323 P237	Neurofilament light chain as early biomarker for hereditary transthyretin amyloidosis – the Swedish experience
400 P238	Neurofilament light chain measurement in hereditary transthyretin-related amyloidosis patients with myocardial sympathetic neuronal damage: substitution for 1231-meta-iodobenzylguanidine scintigraphy?
443 P239	Prevalence of variant genotype in patients with suspected cardiac ATTR amyloidosis
450 P240	Engraftment Syndrome After ASCT is Associated elevated IL-10 and IP-10 (CXCL10) levels
476 P241	Genetic modifiers in hereditary and acquired TTR amyloidosis: a genome-wide association study
122 P242	Skin Biopsy Has A High Diagnostic Yield In Patients With Systemic Amyloidosis And Neuropathy.
179 P243	Assessing amyloid prevalence, type, and extent of burden in the ligamentum flavum of patients with spinal stenosis undergoing routine laminectomy
191 P244	Prevalence of Localized Amyloid in Ligamentum Flavum of Patients with Lumbar Spinal Stenosis
203 P245	Definition of Bone marrow biopsy involvement in amyloidosis – proposal for reporting
214 P246	Detection of amyloid deposits in skin biopsies of patients with clinically suspected variant transthyretin amyloidosis
227 P247	Amyloid deposits are common in different spinal structures among patients with spinal stenosis referred for decompression surgery
236 P248	Diagnosis and typing of pulmonary amyloidosis: A series of cases
253 P249	Concurrent light chain amyloidosis and proximal tubulopathy: insights into different aggregation behavior.
268 P250	Clinicopathological analyses of an autopsied case with hereditary ATTR amyloidosis 22 years after liver transplantation
288 P251	Clinical ApoA-IV amyloid is associated with fibrillogenic signal sequence
303 P252	Removal of Cardiac AL-Amyloid leads to Cardiomyocyte Positive Remodeling and Restrictive Pattern Reversal
309 P253	Degree of transthyretin fragmentation in ATTR amyloidosis tissues
314 P254	Glomerular proteomics – unmasking sub-clinical amyloid or false positive?
332 P255	Complement in amyloidosis – immunohistochemical verification of activation of the complement system in renal light-chain amyloidosis
357 P256	Trends in renal amyloidosis over a 30-year period: Data from the Norwegian Kidney Biopsy Registry 1988 – 2017
358 P257	Clinical and Morphological Phenotypes of AL and ATTR Amyloidosis Detected via Gastrointestinal Biopsies
366 P258	Amyloid deposition in granuloma of tuberculosis patients: A single-center pilot study
375 P259	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 332 patients
425 P260	MANAGING PATIENTS WITH CARPAL TUNNEL SYNDROME AND POSITIVE CONGO RED STAIN: A WORK IN PROGRESS
435 P261	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes
435 P261 445 P262	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis
435 P261 445 P262 451 P263	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice.
435 P261 445 P262 451 P263 453 P264	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series
435 P261 445 P262 451 P263 452 P264 148 P265	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATR amyloidosis Validation of a mouse anti-human Serum Amyloid A ambody immunohistological test for diagnostic clinical practice. Patients with toewing interest systemic amyloidoses – a case series The use of aboutinal fat aspinition biopsy to quantify the amyloid bung long-term follow-up of patients with AA amyloidosis
435 P261 445 P262 451 P263 453 P264 148 P265 274 P266	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloidot Antibody immunohistiological test for diagnostic clinical practice. Patients with two different systemic amyloidoess – a case series The use of abdominal fat aspiration biopsy to quantify the amyloid ouring long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject drugs in OSio, Norway.
435 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coversiting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses - a case series The use of abdominal fat asginization biopsy to quantify the amyloid burden during long-term follow-up of patients with two different systemic amyloidoses Presentation and any object of targs in Osio, Norway. Properties of generic monoclonal A antibodie for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of aboliminal fat aspiration blops to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject drugs in Oslo, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cose / Interion in AA amyloidosis: a high rate of mortality
435 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-humunohisticological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of abdominal fat aspiration biopsy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis in people who inject drugs in Oslo, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cov2 infection in AA amyloidosis: a ligh rate of mortality Clinicopathological characteristics of a Japanee case with fibringen Ac-chain amyloidosis
435 P261 445 P262 451 P263 452 P264 148 P265 274 P266 287 P267 301 P269 164 P269 194 P270	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunchistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of abolinina f1t asginization biopsy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject drugs in Dsio, Norway. Properties of generic monocland. AA antibodig most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cov2 Infection in AA amyloidos: a high rate of mortality Clinicopathological characteristics of a Japanese case with fibringen Au-chain amyloidosis Hereditary Celosinal myloidos: Clinical features from a large cohort in the US
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of aboliminal fat aspiration blogys to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis in people who inject drugs in Oslo, Norway. Properties of generic monoclonal AA antibodies for classfying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cov2 influencion in AA amyloidosis: a high rate of mortality Clinicogathological characteristics of a Japanese case with Tibrinogen Aa-chain amyloidosis Hereditary Gelsolin amyloidodis. Biblings with a novel type of amyloid neuropathy, hereditary AB2M amyloid neuropathy. Report of the second family in the world
135 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 201 P272	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes. Presentation and outcome of patients with coexisting cardia: AL and ATR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of abolimin fat a spinition biops to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject targs in DSIs, Norway. Properties of generic monoclonal AA antibodie for classifying most vertebrate AA amyloidosis. SABS-Cov2 infection in AA amyloidosis: C folloging most vertebrate AA amyloidosis Linicopathological characteristics of a lapanese case with fibringen Aa-chain amyloidosis Hereditary Gelsolin amyloidosis: Clinical features from a large cohort in the US Siblings with a novel type of amyloid moropathy, hereditary ABZM amyloid neuropathy. Report of the second family in the world Apolioportein AV amyloidosis in a Cotto-role tamarin (Saguino usedipus)
335 P261 445 P262 4451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P273	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abolinnial fat aspiration biopsy to quantify the amploid burden during long-term follow-up of patients with AA amyloidosis in people who inject drugs in 050, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cov2 intection in AA antibodies for classifying most vertebrate AA amyloidosis Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis. Properties of generic monoclonal AA antibodies for instative Ad amyloidosis. Properties of generic monoclonal AA antibodies for instative Ad amyloidosis. Properties of generic monoclonal AF antibodies for notality Clinicopathological characteristics of a Japanese case with fibrinogen Ac chain amyloidosis Beilings with a novel type of amyloid burst with anyloid neuropathy: Report of the second family in the world Apoliporotein A-NV amyloidos in a Cotton-top tamarin (Sagunus cedupus) Histobigical and proteomic analyses of semenogenellin 1 amyloid deposits
35 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P279 204 P270 204 P271 211 P272 213 P273 225 P274	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with coexisting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of aboliminal fat aspiration biopsy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in poole who inject drugs in Oslo, Norway. Properties of generic monoclonal AA antibodie for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SAR5-Cov2 infection in AA amyloidosis: of a laspines case with filtringen Aa-chain amyloidosis Clinicopathological characteristics of a laspines case with filtringen Aa-chain amyloidosis Hereditary Gelsolin amyloidosis: Clinical features from a large cohort in the US Stalings with a novel type of amyloid neuropathy, hereditary Ag2M amyloid neuropathy: Report of the second family in the world Apolipopretien ArVa amyloidosis in a Cotton-top tamarin (Saguinus cedipus) Histological and proteomic analyses of semenogelin 1 amyloid deposits Mass spectromeric-mork analyse of adsorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads.
135 P261 445 P262 451 P263 453 P264 148 P265 274 P266 187 P267 301 P269 164 P269 194 P270 204 P271 211 P272 213 P275	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of abolinnial fat aspiration biopsy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis in people who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cos2 Infection in AA amyloidos: a high rate of mortality Clinicopathological characteristics of a Japanese case with fibrinogen Ac-chain amyloidosis Hereditary Gelsonian myloidosis: Clinical features from a large cohort in the US Siblings with a novel type of amyloid autoropathy, hereditary AB2M amyloid neuropathy; Report of the second family in the world Apolipoprotein A-W amyloidosis in a Cotton-top tamarin (Saguinus celipus) Histological and proteomic analysis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings is subjects with an amyloidoportein A1 mutation
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 204 P271 211 P273 225 P274 369 P275 369 P276	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes Presentation and outcome of patients with covisiting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abdominal fat asginization biopsy to quantify the amploid burden during long-term follow-up of patients with toxing for classifying most vertebrate AA amploidoses, and as probes for innate functions of SAA Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amploidoses. SAR5-Cov2 Infection in A A amploidoss: on a log and cover and a sprobes for innate functions of SAA Clinicopathological characteristics of a Japanese case with filtringen Aa-chain amploidosis Benal amploidosis in a cover for classifying most vertebrate AA amploidosis Hereditary Gesolin amploidos: Clinical features from a large cohort in the US Sblings with a novel type of amploid neuropathy. Report of the second family in the world Apollpoprotein A-IV amploidos is in a Cotton-top tamarin (Saguinus cedipus) Histological and proteomic analyses of semenogenin 1 amploid devises related amploidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amploid device related with dialysis-related amploid cellulose beads. Echocardiographic findings in subjects with an amploid devices related with dialysi
435 P261 445 P262 4451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P272 213 P273 269 P274 369 P275 394 P276 474 P277	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoes: – a case series The use of abolimin fat aspiration biopsy to quantify the amploid buildend uring long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject trugs in Osio, Norway. Properties of generic monoclonal AA antibodie for classifying most vertebrate AA amyloidosis. SABS Cov2 infection in AA amyloidosis: Clinical practe of classifying most vertebrate AA amyloidosis. Clinicopathological characteristics of a Japanese case with flurinogen Ag-chain amyloidosis Hereditary Celssolin amyloidosis. Clinical Fatures of roma large cohort in the US Sblings with a novel type of amyloid oses in actions of standing education and yolidogenic analysis. Histological and proteomic analysis of stachorder molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Histological and proteomic analysis of aschorder molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidogenic apolpoprotein A1 mutation Mass spectromery based proteomic analysis of akorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads.
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 204 P271 211 P273 225 P274 369 P275 369 P276	RNA-sequencing reveals similarity of AL amyloidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with cosising cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amyloidoses - a case series The use of abdominal fat aspiration biopsy to quantify the amyloid burden during long term follow-up of patients with that amyloidosis Renal amyloidosis in poople who inject furgis in Dsio, Norway. Properties of generic monoclonal A antibodies of classifying most vertebrate AA amyloidosis SAR5-Cov2 infection in AA amyloidoss: a high rate of mortality Clinicopathological characteristics of a Japanese case with fibringen Aa chain amyloidosis Dialogical characteristics of a Japanese case with Biringen Ra chain amyloidosis Hereditary Gesolin amyloidosis in a Cotton-top tamarin (Saguinus cedipus) Histological and proteomic analysis of adsorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidosis related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidosis and kidney transplantation interface Mass spectrometry-based proteomic analysis of adsorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with a amyloidogenit
135 P261 445 P262 451 P263 452 P264 148 P265 274 P266 287 P267 301 P268 164 P270 204 P271 213 P273 225 P274 369 P275 394 P278 131 P278	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A ambbody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoes: – a case series The use of abolimin fat aspiration biops to quantify the amploid builden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject trugs in Osio, Norway. Properties of generic monoclonal AA antibodie for classifying most vertebrate AA amyloidosis. SABS Cov2 infection in AA amyloidosis: Clinical practe of classifying most vertebrate AA amyloidosis. Glinicopathological characteristics of a Japanese case with flivinogen Aq-chain amyloidosis Hereditary Celssolin amyloidosis: Clinical Patient Forma large cohort in the US Sblings with a novel type of amyloid oses in action toring usedipus). Histological and proteomic analysis of stached mecorpathy: Report of the second family in the world Apolioportein AIV-amyloidosis in a Cotto-role service strated equations endipolicy in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidoposis in hexadecyl-immobilized cellulose beads. Histological and proteomic analysis of aschored molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic fi
135 P261 445 P262 4451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P270 204 P271 211 P272 213 P273 225 P274 369 P276 474 P276 474 P278 131 P278 151 P279	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Validation of a mouse anti-human Serum Amyloid A antibody immunchistological text for diagnostic clinical practice. Patients with two different systemic amyloidoses – a case series The use of abolinnial fat aspiration biopsy to quantify the amyloid barden during long term follow-up of patients with AA amyloidosis in people who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SARS-Cos2 Infection in AA amyloidos: a high rate of mortality Clinicopathological characteristics of a Japanese case with fibrinogen Ac-chain amyloidosis Apolipoprotein A-IV amyloidosis: In a figh rate of mortality Clinicopathological characteristics of a Japanese cont in the US Siblings with a novel type of amyloid osci of from a large cohort in the US Siblings with a novel type of amyloid sis of deposits Apolipoprotein A-IV amyloidosis in a Cotton-top tamarin (Saguinus cedipus) Histological and proteomic analysis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with a amyloid dosis in polycloportein A.I mutaton Iatrogenic cerebral amyloid aniopopatity Fibrinogen A a
335 P261 445 P262 4451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P272 213 P273 394 P276 394 P276 131 P278 151 P279 172 P280	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with coexisting cardia: AL and ATR amploidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoes: – a case series The use of abolinin fat a spinition biops to quantify the amyloid barden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject targs in Dsio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis. SAR5-Cov2 infection in AA amyloidosis con classifying most vertebrate AA amyloidosis Identication and a variability of a lagnese case with fibrinogen Aa-chain amyloidosis Identication and yoldosis. Clinical features from a large cohort in the US Siblings with a novel type of amyloid oxis. Clinical features from a large cohort in the US Siblings with a novel type of amyloid decise rated with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Histological and proteomic analyses of semenogenin 1 amyloid deposits Mass spectromeric vased proteomic analysis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 mutation Iatrogenic cerebral amyloid algopathy <tr< td=""></tr<>
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P279 204 P271 211 P272 225 P274 369 P276 374 P276 131 P278 151 P279 132 P278 134 P280 237 P281	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with covisiting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abdominal fat aspiration biopy to quantify the amploid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in poole who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis. SAR5-Cov2 infection in AA amyloidosis: a lab rate of mortality. Clinicopathological characteristics of a Japanese case with filtringen Aa-chain amyloidosis Biblings with a novel type of amyloid neuropathy, hereditary ABA amyloid neuropathy: Report of the second family in the world Apolipopreties in a cotter or basis of actoretistic serve state with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloid deposits Mass spectromerix -abasis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with a amyloid deposits Mass spectromerix -abasis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic f
435 P261 445 P262 4451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 213 P272 213 P273 369 P275 394 P276 131 P278 151 P279 172 P280 237 P281 246 P282	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abolinnis f1t aspiration biopsy to quantify the amploid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in people who inject drugs in Dsio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis. SARS-Cov2 Infection in AA amyloidosis: a high rate of mortality Clinicopathological characteristics of a Japanese case with fibringen Aa-chain amyloidosis Hereditary Gelsonia myloidosis: in a toring cohort in the US Siblings with a novel type of amyloid neuropathy, hereditary AB2M amyloid neuropathy: Report of the second family in the world Apolioportein AI-M amyloidosis in a Cotton-role mannin (Saquinus cedipus) Histological and proteomic analysis of astorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic finding is subjects with an amyloid deposits Mass spectrometry-based proteomic analysis of astorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic finding is subjects with an amyloidogencapolipoprotein A1 mutation
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P273 225 P274 369 P275 394 P276 131 P278 151 P279 122 P280 237 P281 246 P282 256 P283	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with covisiting cardiac AL and ATTR amploidosis. Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoes - a case series. The use of Jabofinial f1 a signification biogys to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis. Renal amyloidosis in people who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis. Glinicopathological characteristics of a Japanese case with filminogen Aa-chain amyloidosis. Clinicopathological characteristics of a Japanese case with filminogen Aa-chain amyloidosis. Hereditary Gelsolin amyloidosis in a Cotton-top tamarin (Saguinus cedipus). Applicoprotein A-IV amyloidosis in a Cotton-top tamarin (Saguinus cedipus). Mass spectromeric analyses of semenogenin 1 amyloid deposits. Mass spectromeric analyses of semenogenin al anyloid deposits. Rest aduption and that anyloidosis adorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic finding in subjects with an amyloidogenic apolipoprotein A.IV maryloidosis in a Cotton-top tamarin (Saguinus cedipus). Reverter admyloid anyloid neuropathy in patients with relapsed or refractory light cha
435 P261 445 P262 4451 P263 453 P264 454 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 213 P272 225 P274 369 P275 394 P276 474 P277 131 P278 151 P279 237 P281 246 P282 256 P284	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes. Presentation and outcome of patients with coexisting cardiac AL and ATR amploidosis Presentation and outcome of a mouse anti-human Serum Amploidos. Patients with two different systemic amploidoes: – a case series The use of abolimin fat sayination biopsy to quantify the amploid builden during long-term follow-up of patients with AA amploidosis Renal amploidosis in people who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SABS-Cov2 infection in AA amploidosis: Chical Fatures from a large cohort in the US Clinicopathological characteristics of a Japanese case with fibrinogen Aa-chain amyloidosis Hereditary Gelsolin amyloidosis: and control transmin (Saguinus cedipus) Hereditary Gelsolin amyloidosis: and transmin (Saguinus cedipus) Mass spectromic analysis of semenogelin 1 amyloid deposits Mass spectromic analyses of semenogelin 1 amyloid deposits Mass spectromic analysis of schorder molecules related with dialysis-related amyloidosis in hexaderyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 mutation Iatrogenic cerebral amyloid angiopathy Fibringen A Jaha-chain amyloidosi sjource; dialysis and kidney transplantation interface
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 211 P272 213 P273 225 P274 369 P276 374 P276 131 P278 131 P278 237 P281 236 P282 236 P282 236 P284 246 P282 256 P284 263 P284	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with covising cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoes – a case series The use of above: a popel who inject trugs in Oslo, Norway. Properties of generic monoclonal A antibodies for classifying most vertebrate AA amploidoes. SAR5-Cov2 Infection in A amploidoes: a lay and provide a series Clinicopathological characteristics of a Japanese case with fibringen Aa-chain amploidosis Clinicopathological characteristics of a Japanese case with fibringen Aa-chain amploidosis Hereditary Gelsolin amploidos: in a Cotton-top tamarin (Saguinus cedipus) Apolipaprotein A-HV amploid anovoltary the readiavy ABAD amploid neuropathy: Report of the second family in the world Apolipaprotein A-HV amploidos: in a dostoneed molecules related with dialysis-related amploidosis in hexadecyl-immobilized cellulose beads. Echocardiographic finding in subjects with an amploidoeucul stratege or related amploid dosis and with transtyrerin amploid dosis and with transtyrerin amploid dosis and with transtyrerin amploid actored the related amploid dialysis and kidney transplantation interface NUCC019-ODU, a humanized monoclonal antibody, combined with anterface MINC0201-0DU, a humanized monoclonal antibodio scies and point dosi
435 P261 445 P262 4451 P263 453 P264 453 P264 148 P265 274 P266 287 P267 301 P268 164 P270 204 P271 211 P272 213 P273 259 P274 369 P276 474 P270 131 P278 151 P279 172 P280 237 P281 266 P282 266 P283 266 P283 266 P284 296 P285 307 P286	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with coisesiting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abdominal fat aspinistic on biopy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in popel who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA SAR5-Cov2 infection in AA amyloidosis: Collical features from a large cohort in the US Stalings with a novel type of amyloid neuropathy, herediarry AB2M amyloid neuropathy: Report of the second family in the world Apoligoprotein AV-4 amyloidosis in a Cotto-role tramarin (Saquinus cedipus) Histological and proteomic analyses of semengelin 1 amyloid doposits Mass spectromeric analysis of adsorbed molecules related with dialysis-related amyloidosis in hexaderyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 mutation Istrogenic cerevital amyloid anigopathy Fibrinogen A alpha-chain amyloidosis journey: dialysis and kidney transplantation interface Rincocardiographic findings in subjects with transtr
135 P261 445 P262 451 P263 452 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 213 P273 225 P274 369 P275 394 P276 131 P278 137 P280 237 P281 246 P282 265 P284 266 P283 263 P284 264 P282 263 P284 264 P282 263 P284 264 P285 267 P284 263 P284 264 P285 267 P285	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes Presentation and outcome of patients with covisiting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic and ATTR amploido up on patients with patients with present systemic and provide bard of the present of anotice antify the amploidous in popel who inject drugs in Oslo, Norway. Properties of generic monoclonal A antibodies for classifying most vertebrate AA amyloidosis. SAR5-Cov2 Infection in AA amyloidosis: a of a Norse ace with fibringen Aa-chain amyloidosis. Clinicopathological characteristics of a Japanese case with fibringen Aa-chain amyloidosis. Clinicopathological characteristics of a Japanese case with fibringen Aa-chain amyloidosis. Hereditary Gelsolin amyloidous: In a Cotton-top tamarin (Saguinus cedipus). Histological and proteomic analysis of adsorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic finding in subjects with an amyloidosin, analysis of adsorbed molecules related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic finding in subjects with an amyloidosin amyloid dosis in theradecyl-immobilized cellulose beads. Echocardiographic finding in subjects with an amyloidodin monother apy in patients with legaced or refractory light chain amyloidosis: results from a phase 2 toudy py the European Myeleom Network
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P279 204 P271 211 P272 213 P273 269 P274 369 P275 394 P276 474 P278 151 P278 151 P278 237 P281 246 P282 256 P283 263 P284 264 P285 307 P286 328 P287 329 P288 324 P289 325 P280	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with covisiting cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abdominal fat aspiration biogy to quantify the amploid burden during long-term follow-up of patients with AA amyloidosis Renal amyloidosis in poole who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis SABS-Cov2 infection in AA amyloidosis of a Dasnese case with filmingen Aar-chain amyloidosis Clinicopathological characteristics of a Japanese case with Simingen Aar-chain amyloidosis Hereditary Gelsolin amyloidosis in a Cotton-top tamarin (Sagunus cedipus) Histological and proteomic analyses of semenogenin 1 amyloid deposits Mass spectromic analyses of semenogenin anyloidogenic apolipoprotein A1 mutation Istorgenic Cerearia amyloid angosthy Fibringen A alpha-chain amyloidogenic apolipoprotein A1 mutation Efficience 1 amyloid angosthy Fibringen A alpha-chain amyloidogin post with reasplantation interface NNC6019-0001, a bumanized monoclonal antibody, in patients with relapsed or refractory light chain amyloidogsis a phase 2, randomized, placebo-controlled trial
335 P261 445 P262 4451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P272 213 P273 369 P275 394 P276 474 P278 151 P278 226 P281 226 P281 236 P284 296 P285 307 P286 328 P287 329 P288 354 P289	RNA-sequencing reveals similarity of AL amploidosis and MGUS aberrant cells along with several potential target genes. Presentation and outcome of patients with coexisting cardiac AL and ATR amploidosis Validation of a mouse anti-human Serum Amploidoses – a case series The use of abolinnis fat sapiration biopsy to quantify the amploidosis (and part of a mouse anti-human Serum Amploidoses) Patients with two different systemic amploidoes – a case series The use of abolinnis fat sapiration biopsy to quantify the amploid burden during long-term follow-up of patients with AA amploidosis Renal amploidosis in people who inject trugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate A amyloidosis Hereditary (elsolin amyloidosis: Clinical Fatures from a large cohort in the US Shilings with a novel type of amyloid neuropathy, hereditary ABZM amyloid neuropathy: Report of the second family in the world Apolioportein AIV-amyloidosis in a Cotto-role tranarin (Saguinus cedipus) Histological and proteomic analysis of aschordet moleculus related amyloidosis in hexadecyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidogenic apolioportein AI mutation Iatrogenic cerebral amyloidos giource; dialysis and kidney transplantation interface NNCG019-0001, a humanized monochorai antibody, in patients with transplantory light chain amyloidosis: a phase 2 study design of a phase 2, randomized, placebo-controlled trial Efficacy a
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P273 225 P274 369 P275 394 P276 171 P278 151 P278 151 P278 152 P281 266 P281 266 P281 267 P281 277 P280 237 P281 246 P282 256 P283 267 P284 268 P285 307 P286 328 P287 329 P286 354 P290	RNA-sequencing reveals similarity of AL amploidosis and MGUS abernant cells along with several potential target genes. Presentation and outcome of patients with cosising cardiac AL and ATTR amploidosis Validation of a mouse anti-human Serum Amploid A antibody immunohistological test for diagnostic clinical practice. Patients with two different systemic amploidoses – a case series The use of abdominal fat aspiration biopy to quantify the amploid burden during long-term follow-up of patients with AA amploidosis Renal amploidosis in poole who inject drugs in Osio, Norway. Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidosis. Clinicopathological characteristics of a Japanese case with filmingen Aa-chain amyloidosis Clinicopathological characteristics of a Japanese case with filmingen Aa-chain amyloidosis. Hereditary Gelsolin amyloidos in a Cotton-top tamarin (Saguinus cedipus) Hereditary Gelsolin amyloid denoropathy, hereditary Aβ2M amyloid neuropathy: Report of the second family in the world Apolipoprotein A-IV amyloidosis in a Cotton-top tamarin (Saguinus cedipus) Histological and proteomic analysis of schored molecule related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads. Ethocardiographic finding in subjects with an amyloidogenic apolipoprotein A1 mutation Istrogenic cerevita amyloid anigopathy Fibringen A alpha-chain amyloidodis in conotherary in patients with transphritetin amyloidosis, o
335 P261 445 P262 451 P263 453 P264 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 213 P272 214 P270 225 P274 369 P275 394 P276 474 P270 131 P278 151 P279 127 P280 236 P283 266 P283 266 P284 296 P284 296 P284 296 P284 296 P284 296 P284 297 P280 354 P290 359 P291	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis Patients with two different systemic gradiac AL and ATTR amyloidosis Patients with two different systemic cardiac AL and ATTR amyloidosis Patients with two different systemic cardiac AL and ATTR amyloidosis Renal amyloitosis in people who inject drugs in OSio, Norway. Properties of generic monoclonal A antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA Collicitopathological characteristics of a Japanese case with Birningen Aa-chain amyloidosis Cilicitopathological characteristics of a Japanese case with Birningen Aa-chain amyloidosis Dislings with a novel type of amyloid neuropathy. Incerdiary Ag2M amyloid neuropathy, incerdiary Ag2M amyloid neuropathy. Incerdiary Ag2M amyloid neuropathy, incerdiary Gabina amyloidose, nano ediposits Mass spectrometry-based proteomic analysis of Jadorbed molecules related amyloidosis in hexadeyl-immobilized cellulose beads. Echocardiographic findings in subjects with an amyloidogenic apolloportein AI mutation Introgen A alpha-chain amyloid dogenic apolloportein AI mutation Introgen A alpha-chain amyloi
335 P261 445 P262 451 P263 453 P264 148 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P272 213 P273 225 P274 369 P275 394 P276 131 P278 151 P278 256 P283 266 P282 277 P281 287 P284 296 P285 307 P286 328 P287 328 P289 359 P290 400 P292 424 P293 424 P294	RNA-sequencing reveals similarity of AL amyloidous and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with consisting cardac AL and ATR amyloidous Valiation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice. Patients with to odisting cardae XL and ATR amyloidous Renal amyloidous in poole wind in pool for the cards of the cards of the cards of the card patients with AA amyloidous antibodies for classifying most vertebrate AA amyloidous, and as probes for innate functions of SAA SAR5-Cox2 infection in AA amyloidous: A nilp rate of mortally Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidous Chincopathological characteristics of a Japanese case with Birringer Ac-chain amyloidous Chincopathological characteristics of a Japanese case with Birringer Ac-chain amyloidous Apologorotin A-Y amyloidous is a Ottor to tamarin (Saguino ediqus) Histological and proteomic analysis of adorbed molecules related with dialysis-related amyloidous in hexadecyl-immobilized cellulose beads. Echocarciticagraphic findings in subjects with an amyloidoosis jurnery: (Japiss and Kidney transplantation interface NNEGOSD-0001, a humanized monoclonal antibody, in patients with transtryretin amyloid cardio mylopathy (ATTR CM): rationale and study deging of a phase 2, randomized, placebo controlled trial Effeca van das face / obelatmathab and dototion monochiner aninyloid dopoists Anta
35 P261 445 P262 451 P263 453 P264 454 P265 274 P266 287 P267 301 P268 164 P269 194 P270 204 P271 211 P272 213 P273 259 P274 369 P276 474 P276 474 P276 131 P278 151 P279 172 P280 236 P284 266 P283 266 P283 266 P284 296 P285 307 P286 354 P290 407 P290 407 P291 410 P292 424 P293	RNA-sequencing reveals similarity of AL annyloidosis and MGUS aberrant cells along with several potential target genes Presentation and outcome of patients with coexisting cradiac AL and ATR annyloidosis Patients with two different systemic annyloidoses – a cass series Patients with two different systemic annyloidoses – a cass series Properties of generic monoclonal At antibodies for classifying motive term follow-up of patients with AA annyloidosis: Reral annyloidosis in people who inject drugs in Diso, Norway. Properties of generic monoclonal AA antibodies for classifying moti vertebrate AA annyloidoses, and as probes for innate functions of SAA SAR5-Cox2 Infection in AA annyloidosis: a light rate of mortality Clinicopathological characteristics of a Japances case with fibringgen Ac-chain annyloidosis Elevel data of potomic annological characteristics of a Japances case with fibringgen Ac-chain annyloidosis Hereditary GEstolin annyloidosis: a Cotton-top tamarin (Saguinus cedipus) Histobiggical and portoonic annalybic eleverstrip annyloid oeuropathy, Report of the second family in the world Apolipoprotein A-Y annyloidosis in a Cotton-top tamarin (Saguinus cedipus) Mass spectrometry-based groteomic analysis of absched molecules related with dialysis-related annyloidosis in hexaderyl-immobilized cellulose bads. Echocardiagraphic findings in subjects with an annyloidogenic apolipoprotein A1 manyloidosis Nuc6019-000. Jumarated monoclonal antibod